Callisto Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 1609
New York,
NY 10170
United States - Map
Phone: 212-297-0010
Web Site: http://www.callistopharma.com
| Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights. Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Gabriele M. Cerrone , 36
Chairman and Consultant |
N/A
| N/A | Dr. Gary S. Jacob Ph.D., 62
Chief Exec. Officer, Chief Scientific Officer, Exec. Director, Chairman of Synergy Pharmaceuticals Inc, Acting Chief Exec. Officer of Synergy Pharmaceuticals Inc and Pres of Synergy Pharmaceuticals Inc |
N/A
| N/A | Mr. Bernard F. Denoyer CPA, M.B.A., 61
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec. |
$
201.00K | N/A | Mr. Kunwar Shailubhai Ph.D., 51
Chief Scientific Officer of Synergy Pharmaceuticals Inc |
N/A
| N/A | Dr. Robert C. Shepard M.D. F.A.C.P.,
Chief Medical Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 
Profile
